Nearly three million people worldwide live with multiple sclerosis, a chronic disease in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. In the United States alone, close to one million people are living with MS, according to a landmark study that found the figure was more than double what had previously been assumed. Global prevalence rose from about 2.3 million people in 2013 to 2.8 million in 2020, and the number keeps climbing, according to data cited by NEWMEDIAWIRE.
Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability. This gap is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its lead drug candidate, Lucid-MS.
Lucid-MS is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2. This mechanism distinguishes it from existing therapies, which primarily modulate the immune system but do not directly address the loss of myelin that underlies disability progression. By focusing on the biological process of demyelination itself, Quantum BioPharma aims to develop a treatment that could potentially slow or halt the damage that leads to long-term disability.
The company’s efforts come as the MS landscape shows a growing patient population and a persistent lack of options for progressive forms of the disease. The global prevalence rose from about 2.3 million people in 2013 to 2.8 million in 2020, underscoring the urgent need for new therapies. While many approved treatments can reduce relapses in relapsing-remitting MS, they have limited effect in progressive MS, where disability accumulates steadily. Lucid-MS, if successful, could offer a novel approach that addresses this unmet need.
Quantum BioPharma is a publicly traded company listed on NASDAQ under the ticker QNTM. Its work on Lucid-MS represents a strategic bet on a differentiated mechanism that could complement or eventually replace existing treatment paradigms. For investors and patients alike, the progress of this candidate will be closely watched as it moves through preclinical and clinical development. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
As with any drug development program, there are significant risks and uncertainties. Forward-looking statements about Lucid-MS are subject to factors beyond management’s control, including risks detailed in the company’s SEC filings. Undue reliance should not be placed on such statements when making an investment decision. Nevertheless, the pursuit of a new path for better multiple sclerosis treatments highlights the importance of innovation in addressing a disease that currently has no cure.
